FTO and acute myeloid leukemia: Links between epitranscriptome and cancer have emerged with the discovery that FTO (Fat mass and obesity-associated protein), first identified as the m6A eraser, but recently described as the m6Am (N6, 2′-O-dimethyladenosine) eraser, is abnormally expressed in acute myeloid leukemia [80], and affects the stability and subcellular location of mRNAs [81].